ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0904

Response to Ixekizumab by C-reactive Protein Level in Patients with Radiographic Axial Spondyloarthritis: Results from the COAST-V (Biological-Naïve) and COAST-W (TNF Inhibitor-Experienced) Trials at 52 Weeks

John Reveille1, Proton Rahman2, David Sandoval3, Talia Muran3, Andris Kronbergs3, Rebecca Bolce3, Vladimir Geneus3, Theresa Hunter3, Soyi Liu-Leage4, Martin Rudwaleit5, Jose Maldonado-Cocco6 and Filip Van den Bosch7, 1Department of Internal Medicine, University of Texas, Houston, TX, 2Memorial University of Newfoundland, Department of Medicine, St John's, Canada, 3Eli Lilly and Company, Indianapolis, 4Eli Lilly and Company, Indianapolis, IN, 5Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany, 6University of Buenos Aires School of Medicine, Buenos Aires, Argentina, 7Ghent University Hospital, Ghent, Belgium

Meeting: ACR Convergence 2020

Keywords: Ankylosing spondylitis (AS)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Tumor necrosis factor inhibitors (TNFis) are effective treatments for radiographic axial spondyloarthritis (r-axSpA), but may be less effective in patients (pts) without elevated C-reactive protein (CRP). This study evaluated the efficacy of ixekizumab (IXE), a high-affinity monoclonal antibody selectively targeting interleukin-17A, in pts with r-axSpA at 52 weeks (wks) with nonelevated (≤5 mg/L) and elevated ( >5 mg/L) baseline (BL) CRP. Week 16 Assessment of Spondyloarthritis International Society 40% response rate (ASAS40) results comparing IXE to placebo (PBO) stratified by CRP are published.[1]

Methods: COAST-V (NCT02696785) and COAST-W (NCT02696798) were phase 3, multicenter, randomized, double-blind, PBO-controlled trials investigating efficacy of 80-mg IXE every 4 wks and every 2 wks in pts who met ASAS criteria for r‑axSpA, had radiographic sacroiliitis according to mNY criteria, and were biological disease‑modifying antirheumatic drug (bDMARDs)-naïve (COAST-V) or TNFi‑experienced (COAST-W). Data from 157 COAST-V pts and 188 COAST-W pts treated with IXE from Wk 0 to Wk 52 were analyzed. Patients were stratified based on nonelevated (≤5 mg/L) vs elevated ( >5 mg/L) BL CRP. Additional analysis was done with BL CRP ≤10.0 mg/L vs >10.0 mg/L. Efficacy was assessed by ASAS40, ≥50% improvement in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI50), and change in Short Form 36 physical component summary (SF‑36 PCS) score. Missing data were imputed by non‑responder imputation for binary measures and modified BL observation carried forward for continuous measure. Week 16 data are presented for comparison.[1]

Results: Of pts treated with IXE through Wk 52, 34.4% had CRP ≤5.0 mg/L, 65.6% had CRP >5.0 mg/L, 61.8% had CRP ≤10.0 mg/L, and 38.2% had CRP >10.0 mg/L at BL in COAST‑V and 33.0% had CRP ≤5.0 mg/L, 67.0% had CRP >5.0 mg/L, 55.9% had CRP ≤10.0 mg/L, and 44.1% had CRP >10.0 mg/L at BL in COAST-W.

At Wk 16, the proportion of pts achieving ASAS40 in COAST-V was numerically higher with IXE in the ≤5 mg/L group and significantly higher with IXE in the >5 mg/L group vs PBO, as previously shown [1], and was significantly higher with IXE in the ≤10 mg/L and >10 mg/L groups vs PBO (Fig. 1). Results were similar in COAST-W and significant in the >5 mg/L and ≤10 mg/L groups vs PBO (Fig. 1).

At Wk 52, greater than 45% of COAST-V pts and greater than 35% of COAST-W pts treated with IXE achieved an ASAS40 response, greater than 40% of COAST-V pts and greater than 25% of COAST-W pts treated with IXE achieved a BASDAI50 response, and change from baseline in SF-36 PCS score in pts treated with IXE was greater than 5 points in both studies regardless of the BL CRP cutoffs evaluated (Figs. 2 and 3).

Conclusion: A higher proportion of ASAS40 responders was observed in IXE treated arms versus PBO among bDMARD-naïve and TNFi-experienced pts with r-axSpA when the CRP cutoff of 10 mg/L was evaluated, and the responses were consistent through Wk 52. Furthermore, similar proportions of pts achieved BASDAI50 and SF-36 responses within each patient population regardless of the BL CRP cutoff evaluated.

Reference:

1. Maksymowych et al. 2019

a. Week 16 data for the CRP ≤5 mg/L and >5 mg/L groups were previously published in a COAST V/COAST-W integrated dataset.[1] *p < 0.001, †p < 0.01, ‡p < 0.05 vs PBO, ASAS40=Assessment of Spondyloarthritis International Society 40% response rate; CRP=C-reactive protein; ITT=intent-to-treat; IXE=ixekizumab; N=number of patients in the treatment group; Ns=number of patients in each subgroup; NRI=non-responder imputation; PBO=placebo; Q2W=every 2 weeks; Q4W=every 4 weeks.

Patients in these analyses received at least one dose of IXE Q4W or Q2W through Week 52. Descriptive statistics are provided without inferential testing. ASAS40=Assessment of Spondyloarthritis International Society 40% response rate; BASDAI50=≥50% improvement in Bath Ankylosing Spondylitis Disease Activity Index; CRP=C-reactive protein; IXE=ixekizumab; NRI=non-responder imputation; Ns=number of patients in each subgroup; Q2W=every 2 weeks; Q4W=every 4 weeks.

Patients in this analysis received at least one dose of IXE Q4W or Q2W through Week 52. Descriptive statistics are provided without inferential testing. CRP=C reactive protein; IXE=ixekizumab; mBOCF=modified baseline observation carried forward; Ns=number of patients in each subgroup; SF-36 PCS=Short Form 36 Physical Component Score; Q2W=every 2 weeks; Q4W=every 4 weeks.


Disclosure: J. Reveille, Eli Lilly, 2, UCB, 5, Janssen, 2; P. Rahman, AbbVie, 5, 8, Amgen, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Janssen, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 5, 8, UCB, 5, 8, Abbott, 8, Centacor, 8, Merck, 8, Bristol Myers Squibb, 5, 8, Roche, 5; D. Sandoval, Eli Lilly and Company, 3; T. Muran, Eli Lilly and Company, 1, 3; A. Kronbergs, Eli Lilly and Company, 1, 3; R. Bolce, Eli Lilly and Company, 1, 3; V. Geneus, Eli Lilly and Company, 3, 4; T. Hunter, Eli Lilly and Company, 1, 3; S. Liu-Leage, Eli Lilly and Company, 3, 4; M. Rudwaleit, Bristol-Myers Squibb, 5, 8, Chugai Pharmaceutical Co., Ltd., 5, 8, Eli Lilly and Company, 5, 8, Janssen, 5, 8, Novartis, 5, 8, UCB Pharma, 5, 8, AbbVie, 5, 8, Pfizer, 5, 8, Celgene, 8, Roche, 5, 8, Merck Sharp & Dohme, 5, 8; J. Maldonado-Cocco, Pfizer, 2, 5, 8, Merck Sharp Dohme, 2, 5, 8, Novartis, 2, 5, 8, Sanofi-Aventis, 2, 5, 8, Bristol Myers Squibb, 2, 5, 8, Roche, 2, 5, 8, Boehringer Ingelheim, 2, 5, 8, Schering-Plough, 2, 5, 8, Abbott, 2, 5, 8, UCB, 2, 5, 8, Eli Lilly and Company, 2, 5, 8, Gilead, 2, 5, 8; F. Van den Bosch, AbbVie, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Galapagos, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, UCB, 5, 8, Gilead, 5, Merck, 5, 8.

To cite this abstract in AMA style:

Reveille J, Rahman P, Sandoval D, Muran T, Kronbergs A, Bolce R, Geneus V, Hunter T, Liu-Leage S, Rudwaleit M, Maldonado-Cocco J, Van den Bosch F. Response to Ixekizumab by C-reactive Protein Level in Patients with Radiographic Axial Spondyloarthritis: Results from the COAST-V (Biological-Naïve) and COAST-W (TNF Inhibitor-Experienced) Trials at 52 Weeks [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/response-to-ixekizumab-by-c-reactive-protein-level-in-patients-with-radiographic-axial-spondyloarthritis-results-from-the-coast-v-biological-naive-and-coast-w-tnf-inhibitor-experienced-trials-at/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/response-to-ixekizumab-by-c-reactive-protein-level-in-patients-with-radiographic-axial-spondyloarthritis-results-from-the-coast-v-biological-naive-and-coast-w-tnf-inhibitor-experienced-trials-at/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology